fda tirzepatide update Grants a New Indication for Obesity Management FDA to reconsider removal of
Description
Semaglutide is a once-weekly injection that significantly reduces body weight by enhancing satiety and controlling appetite
momentum further picked up in Q4, said Elara Capital
Concurrently, GLP-1 receptor activation stimulates glucose-dependent insulin release from pancreatic beta cells, suppresses inappropriate glucagon secretion, slows gastric emptying, and reduces appetite through central nervous system pathways
Overall, these findings highlight a potential protective role of GLP-1 RAs in bladder health independent of diabetes status
Self-monitoring: Keep track of your weight, feelings, and any side effects
